Monday, June 2, 2025
6:30 PM – 8:00 PM CT
Please note this virtually live meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific
FACULTY
 |
Stacey A. Cohen, MD Associate Professor Clinical Research Division Fred Hutchinson Cancer Center Associate Professor, Division of Hematology and Oncology University of Washington Seattle, Washington |
 |
Antonia R. Sepulveda, MD, PhD, FACP Chair and Professor, Department of Pathology Ralph E. Loewy Professor of Oncology GW Cancer Center George Washington University School of Medicine and Health Sciences Washington, District of Columbia |
PROGRAM OVERVIEW
This program addresses the importance of comprehensive molecular testing in metastatic colorectal cancer (mCRC) and outlines recent updates in clinical practice guideline recommendations for various molecular tests in mCRC. The program aims to bridge the gap in awareness of clinical trial data for approved targeted and immunotherapies for mCRC, as well as building knowledge of clinical trials that are currently assessing approved second-line treatments in the first-line setting. Additionally, the program is designed to increase awareness of pros and cons for different types of molecular testing available, including their associated sample requirements. Further program focus targets development of individual test strategies and the appreciation of individual practitioner roles as part of a molecular tumor board (MTB).
TARGET AUDIENCE
This educational activity is specifically designed for community oncologists, oncology nurses, and nurse practitioners.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recall clinical practice guideline recommendations for comprehensive molecular testing in mCRC
- Apply understanding of the key clinical trial efficacy and safety data for recently approved targeted therapies and immunotherapies into clinical practice for mCRC, and summarize the emerging evidence for their use in earlier treatment settings
- Describe molecular testing strategies for mCRC and the role of the molecular tumor board (MTB) in interpreting test results
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this virtually live activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
